eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
10 hedge funds and large institutions have $258K invested in eFFECTOR Therapeutics, Inc. Warrant in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
9% less funds holding
Funds holding: 11 → 10 (-1)
43% less capital invested
Capital invested by funds: $454K → $258K (-$196K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$745 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.7K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$620 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Aristeia Capital
Greenwich,
Connecticut
| $161K | -$620 | -4,403 | -0.3% |
|
2
Goldman Sachs
New York
| $47.9K | – | – | – |
|
|
WA
3
Whitebox Advisors
Minneapolis,
Minnesota
| $22.7K | – | – | – |
|
|
MI
4
MMCAP International
Grand Cayman,
Cayman Islands
| $11.1K | – | – | – |
|
|
PA
5
Parallel Advisors
San Francisco,
California
| $4.88K | – | – | – |
|
|
ICM
6
III Capital Management
Boca Raton,
Florida
| $4.51K | – | – | – |
|
|
TCM
7
Tenor Capital Management
New York
| $2.53K | – | – | – |
|
|
SOA
8
Sea Otter Advisors
Miami,
Florida
| $1.9K | – | – | – |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $1.42K | +$745 | +5,290 | +40% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $2 | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$2.7K | -19,692 | Closed |
|
EFTRW Hedge Fund Activity: Q3 2023 in Review
10 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q3 2023, worth a combined $258K — down 43% from $454K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of EFTRW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Wolverine Asset Management, adding an estimated $745. The largest seller was UBS Group, exiting entirely with an estimated $2.7K sold.
- 10 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q3 2023, down from 11 in Q2 2023.
- Funds reported $258K of eFFECTOR Therapeutics, Inc. Warrant stock for Q3 2023, down 43% quarter-over-quarter.
- 0 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q3 2023 was Wolverine Asset Management, an estimated $745 added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q3 2023 was UBS Group, an estimated $2.7K sold.
Based on aggregated 13F filings for Q3 2023.